Family Office Research LLC Purchases Shares of 89,930 CareDx, Inc (NASDAQ:CDNA)

Family Office Research LLC acquired a new position in shares of CareDx, Inc (NASDAQ:CDNA) in the 4th quarter, HoldingsChannel reports. The fund acquired 89,930 shares of the company’s stock, valued at approximately $1,925,000. CareDx makes up 0.8% of Family Office Research LLC’s investment portfolio, making the stock its 21st largest position.

Other large investors also recently made changes to their positions in the company. Quarry LP acquired a new position in CareDx during the 3rd quarter worth approximately $27,000. Plato Investment Management Ltd raised its stake in shares of CareDx by 34.1% during the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company’s stock valued at $116,000 after purchasing an additional 1,370 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in shares of CareDx by 41.5% during the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company’s stock worth $200,000 after purchasing an additional 2,742 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of CareDx in the fourth quarter valued at $208,000. Finally, Cornercap Investment Counsel Inc. acquired a new stake in CareDx during the 4th quarter valued at $214,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a research report on Wednesday, February 26th. Wells Fargo & Company raised CareDx from an “underweight” rating to an “equal weight” rating and cut their target price for the company from $28.00 to $24.00 in a research report on Wednesday, January 15th. HC Wainwright decreased their price target on shares of CareDx from $26.00 to $25.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Finally, Stephens reaffirmed an “overweight” rating and issued a $40.00 price target on shares of CareDx in a report on Thursday, February 27th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.83.

CareDx Trading Down 3.3 %

Shares of NASDAQ CDNA opened at $18.43 on Friday. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -6.83 and a beta of 2.18. CareDx, Inc has a twelve month low of $7.42 and a twelve month high of $34.84. The business has a 50 day simple moving average of $20.31 and a 200-day simple moving average of $22.81.

CareDx (NASDAQ:CDNA) last released its earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, beating the consensus estimate of $0.05 by $1.46. The firm had revenue of $86.58 million during the quarter, compared to analyst estimates of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. As a group, equities analysts predict that CareDx, Inc will post -0.9 earnings per share for the current year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.